Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Nanobiotix ( (NBTX) ) is now available.
Nanobiotix announced on March 26, 2026, that it would release its fourth-quarter and full-year 2025 financial and operational results after the close of the U.S. market on March 31, 2026. The company also scheduled a conference call and webcast for April 1, 2026, during which senior management planned to review year-end performance and provide a business update for investors and analysts.
The timing of the disclosure and accompanying investor call underscores Nanobiotix’s efforts to maintain transparency with shareholders as it advances late-clinical-stage oncology and other therapeutic programs. By pairing its results release with a live Q&A session and archived webcast, the company is aiming to deepen engagement with the market and provide additional context on its strategic and operational progress through 2025.
The most recent analyst rating on (NBTX) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
Nanobiotix’s overall stock score is primarily impacted by its poor financial performance, with significant operational losses and financial instability. While technical analysis shows some positive momentum, the negative valuation metrics due to lack of profitability further weigh down the score.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix S.A. is a late-stage clinical biotechnology company pioneering nanoparticle- and physics-based therapeutic approaches aimed at expanding treatment options for cancer and other major diseases. Founded in 2003 and headquartered in Paris, it is listed on Euronext Paris and the Nasdaq Global Select Market, and holds more than 30 patent families across oncology, bioavailability and biodistribution, and central nervous system disorders.
Average Trading Volume: 42,918
Technical Sentiment Signal: Buy
Current Market Cap: $1.49B
See more data about NBTX stock on TipRanks’ Stock Analysis page.